ethambutol has been researched along with methotrexate in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Akhter, M; Alam, MM; Ali, S; Deora, GS; Krishna, VS; Sharma, K; Sriram, D; Tanwar, O; Zaman, MS | 1 |
| Bera, S; Mondal, D | 1 |
| Böcher, W; Galle, PR; Märker-Hermann, E | 1 |
| Caron, J; Dereure, O; Fabre, S; Godreuil, S; Guillot, B; Michot, C | 1 |
| Peña-Santos, G; Ruiz-Moreno, JL | 1 |
| Hosoda, C; Ishiguro, T; Kanegane, H; Shimizu, Y; Takayanagi, N | 1 |
2 review(s) available for ethambutol and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
14 other study(ies) available for ethambutol and methotrexate
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Indoles; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2019 |
[Skin nodules and ulcers of the limbs in a patient with rheumatoid arthritis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Biopsy; Ciprofloxacin; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Extremities; Glucocorticoids; Humans; Immunocompromised Host; Male; Methotrexate; Middle Aged; Mycobacterium Infections, Nontuberculous; Mycobacterium marinum; Prednisolone; Skin Diseases, Bacterial; Skin Ulcer; Vasculitis | 2002 |
Aggressive cutaneous infection with Mycobacterium marinum in two patients receiving anti-tumor necrosis factor-alfa agents.
Topics: Adult; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Arthritis, Psoriatic; Arthritis, Rheumatoid; Bacterial Typing Techniques; Clarithromycin; Ethambutol; Female; Fingers; Fishes; Hand Dermatoses; Humans; Immunocompromised Host; Immunosuppressive Agents; Infliximab; Methotrexate; Middle Aged; Minocycline; Mycobacterium Infections, Nontuberculous; Mycobacterium marinum; Rifabutin; Skin Diseases, Bacterial; Tumor Necrosis Factor-alpha | 2011 |
[Bilateral tuberculous mastitis nulliparous patient, initially treated as idiopathic granulomatous mastitis].
Topics: Adult; Antitubercular Agents; Diagnostic Errors; Drug Therapy, Combination; Ethambutol; Female; Granulomatous Mastitis; Humans; Isoniazid; Mastitis; Methotrexate; Mycobacterium tuberculosis; Polymerase Chain Reaction; Prednisone; Pyrazinamide; Recurrence; Rifampin; Tuberculosis | 2012 |
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Bronchoscopy; Clarithromycin; Ethambutol; Glucocorticoids; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Methotrexate; Mycobacterium; Mycobacterium Infections, Nontuberculous; Nucleic Acid Amplification Techniques; Polymyalgia Rheumatica; Polyps; Prednisolone; Pulmonary Atelectasis; Rifampin; Tomography, X-Ray Computed; Treatment Outcome; Tuberculosis, Pulmonary | 2020 |